Pluvicto drug
Ended Awarded
- Contract number
- 36C26126F0007
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $3,987,497
Award facts
- Contract value 100% obligated
- $3,987,496.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 21, awarded a $3.99M firm fixed-price delivery order to Novartis Pharmaceuticals Corporation for PLUVICTO, a radiopharmaceutical cancer therapy treatment, with performance based in East Hanover, New Jersey and completion targeted for September 30, 2026. The award, issued on October 1, 2025, utilizes no small business set-aside designation, allowing Novartis to compete as a large pharmaceutical manufacturer in the federal marketplace. This delivery order is placed against Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), enabling the VA to procure specialized medical treatments through established pricing and terms.
This award represents one of several delivery orders Novartis has received from VA networks for PLUVICTO and related radiopharmaceuticals. The company maintains significant federal contract vehicles dedicated to cancer therapy procurement, including a $7.48M Blanket Purchase Agreement with VA's Integrated Service Network 10 through September 2030 and a $26.10M Indefinite Delivery Contract with the Defense Health Agency covering multiple cancer therapy drugs through September 2029. These contracts underscore Novartis' established role as a key supplier of advanced oncology treatments to federal healthcare systems supporting veteran care.
Quick answers
Who was awarded contract 36C26126F0007?
36C26126F0007 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 1, 2025.
How much is contract 36C26126F0007 worth?
The government has obligated $3,987,497 on 36C26126F0007.
Is contract 36C26126F0007 an order under another contract?
Yes. 36C26126F0007 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126F0007 competed?
The extent of competition for 36C26126F0007 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award